PEspeaks

Sep 25, 2017
While biopharma companies have pressed hard for clarity on the data required to gain market approval of biosimilars that can be filled by a pharmacist without prescriber pre-approval, the progress towards "interchangeability" has been slow. Jill Wechsler reports.
Sep 20, 2017
Pharmaceutical Executive
This article discusses email marketing opportunities through the lens of 1999's dramatic comedy, She's All That.
Sep 11, 2017
In the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Capture.
Sep 07, 2017
Pharmaceutical Executive
Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.
Sep 06, 2017
Pharmaceutical Executive
A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission—giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.
Sep 05, 2017
Reflector asks if the UK's newly announced post-Brexit life sciences strategy report is worth a look as a springboard to addressing future EU ties in healthcare, or just more bluster?
Sep 05, 2017
Neil Grubert reviews the UK’s post-Brexit life sciences strategy, with a particular focus on the key area of market access.
Sep 04, 2017
Leela Barham casts her eye over the UK's plans for its life sciences industry in the post-Brexit world.
Aug 31, 2017
Funso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.
Aug 10, 2017
In the first of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Creation.
native1_300x100
lorem ipsum